Takeda’s flagship experimental cancer drug ixazomib is a giant leap closer to being filed with regulatory authorities around the globe for multiple myeloma, after turning in a solid performance in late-stage trials.
Takeda’s ixazomib soon to be filed for multiple myeloma
Read more at:
Filed under: Phase3 drugs Tagged: Ixazomib, multiple myloma, TAKEDA
